BC Extra | Jun 28, 2019
Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

Anti-glycan mAb licensed by BioNTech could prevent pancreatitis  A Science study from Cold Spring Harbor Laboratory suggests the glycan CA19.9 (sialyl Lewis A), long known as a biomarker of pancreatic disease, actively drives the progression...
BC Extra | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
BC Week In Review | Mar 9, 2018
Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported interim data from three patients with CA19.9-positive malignancies in the first cohort of a Phase I trial showing that MVT-1075 was well tolerated and accumulated on target lesions as...
BC Week In Review | Nov 30, 2017
Clinical News

Berg reports Phase II data for ubidecarenone in metastatic pancreatic cancer

In September, Berg LLC (Framingham, Mass.) reported data from 5 evaluable patients with advanced pancreatic cancer in a Phase II trial showing that second-line treatment with IV ubidecarenone (Coenzyme Q10; BPM 31510) alone or in...
BC Innovations | Nov 2, 2017
Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
BC Week In Review | Jul 7, 2017
Clinical News

MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) began an open-label, U.S. Phase I trial to evaluate escalating doses of MVT-1075 in about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive cancers who have failed...
BC Week In Review | Jun 9, 2017
Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported data from 32 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ia trial showing that IV MVT-5873 (5B1 antibody, HuMab-5B1) led to...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
BC Week In Review | Jun 29, 2015
Clinical News

Nanoplatin: Phase III ongoing

NanoCarrier said it submitted an IND in Japan to add Japanese patients to an ongoing, open-label, Asian Phase III trial comparing 90 mg/m 2 IV Nanoplatin given every 3 weeks plus gemcitabine vs. gemcitabine alone...
BC Week In Review | Oct 20, 2014
Clinical News

Necuparanib: Phase I/II data

Top-line data from 12 evaluable patients with advanced metastatic pancreatic cancer in the open-label, dose-escalation, U.S. Part A of a Phase I/II trial showed that once-daily oral necuparanib plus Abraxane nab-paclitaxel and gemcitabine led to...
Items per page:
1 - 10 of 18